evipedia.ai
← Back

Low-Dose Aspirin for Health & Longevity

Evidence Review created on 10/22/2026 using AI4L / Opus 5.5

Also known as: Aspirin, Acetylsalicylic Acid, ASA, LDA, Baby Aspirin, Low-Dose ASA, Bayer Aspirin, Ecotrin, Aspirin Protect, Cardioaspirin

Motivation

Low-dose aspirin is a daily oral tablet of 75 to 100 milligrams of the same drug long used for pain and fever. At this small dose it mainly makes the blood’s clotting cells less sticky for their whole lifespan, which is why it has been used for decades in efforts to prevent blood clots in arteries. For people focused on staying healthy for longer, it is attractive because it is cheap, widely available without a prescription, and has been studied in very large numbers of people.

For years, many healthy middle-aged and older adults took a daily “baby aspirin” in the belief that it would guard against heart attack and stroke. Interest widened when long-term follow-up of older heart studies raised the question of whether it might also affect the chance of some cancers, especially bowel cancer, and when it was tested as a possible life-extending drug in animals.

This review examines what human trials and supporting studies show about the benefits and harms of daily low-dose aspirin for heart and blood-vessel disease, cancer and healthy lifespan, and which personal factors shift that balance.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and overview articles that discuss daily low-dose aspirin in depth.

  • 4 Natural Alternatives to Aspirin - Chris Kresser

    A podcast episode weighing the bleeding risks of daily low-dose aspirin against its clot-prevention value. Kresser, whose company sells supplements, then discusses non-drug alternatives.

  • The Everyday Drug That Prevents Cancer Death - Edward Korlov

    An advocacy article from a supplement retailer promoting daily 81 mg aspirin to lower cancer death, built on pooled Oxford trial analyses; it predates trials in older adults that found no such benefit.

  • Platelet activation, aspirin, and cancer: From basic science to clinical trials. - Patrono et al., 2026

    Leading aspirin researchers review how platelet activation may drive bowel cancer and its spread, and summarize recent trials in inherited bowel-cancer syndromes and genetically defined tumors.

Note: Only three items qualify. Lifespan.io covers low-dose aspirin only in short news reports on single studies (e.g., a 2022 cohort analysis of dementia), not as an in-depth overview, so it is not listed. Peter Attia’s in-depth discussion (AMA #76) and Rhonda Patrick’s (Q&A #30) are members-only, so they are not listed; Attia’s free episode #103 covers baby aspirin only in a brief segment on why he stopped taking it, too short to qualify. No Andrew Huberman (hubermanlab.com) episode or article on daily low-dose aspirin was found; aspirin appears there only as a pain reliever in exercise-recovery discussions.

Grokipedia

  • Aspirin

    A broad reference article on aspirin that includes sections on cardiovascular and cancer prevention, current guideline positions and dosing, useful as a quick general orientation.

Examine

No Examine article on low-dose aspirin exists. Examine covers aspirin only through short summaries of individual studies in its research feed, not through a dedicated page.

ConsumerLab

No ConsumerLab article on low-dose aspirin exists. ConsumerLab mentions aspirin only within articles on other topics, such as supplement interactions with anticoagulants (drugs that block clotting factors).

Systematic Reviews

This section lists systematic reviews and meta-analyses covering both the protective effects and the bleeding risks of daily low-dose aspirin.

Mechanism of Action

Low-dose aspirin acts mainly by permanently disabling one enzyme in platelets, the cell fragments that start blood clots (Patrono et al., 2005).

  • Platelet enzyme blockade: Aspirin attaches an acetyl group to cyclooxygenase-1 (COX-1, the enzyme that makes prostaglandin and thromboxane signals), blocking it irreversibly. Platelets cannot make new enzyme, so thromboxane A2 (TXA2, a signal that makes platelets clump) stays suppressed for the platelet’s 7–10-day lifespan.
  • Why the dose is low: At 75–100 mg, the effect occurs mostly in gut and liver blood, largely sparing vessel-wall prostacyclin (PGI2, an anti-clotting signal); higher doses add the anti-inflammatory effects of NSAIDs (nonsteroidal anti-inflammatory drugs, the ibuprofen-type class).
  • Competing anticancer explanations: One view: calmer platelets reduce COX-2 (cyclooxygenase-2, the inflammation-induced form) and prostaglandin E2 (PGE2, a growth-promoting signal) in the bowel lining and stop shielding tumor cells (Patrono et al., 2026). Others propose direct effects on tumors with an overactive PI3K pathway (phosphoinositide 3-kinase, a cell-growth route) (Liao et al., 2012) or blockade of EP300 (an enzyme that adds acetyl tags to proteins), triggering autophagy (cellular self-cleaning) (Pietrocola et al., 2018).
  • Pharmacology: Aspirin is broken down in the blood to salicylic acid within 1–2 hours. Salicylic acid (half-life about 6 hours) is widely distributed, about 90% bound to albumin (the main blood protein), converted in the liver into salicyluric acid and glucuronic-acid compounds, and excreted in urine (US labeling, 21 CFR 343.80); glucuronidation uses UGT enzymes (UDP-glucuronosyltransferases, which attach glucuronic acid for excretion) (Kuehl et al., 2006).

Historical Context & Evolution

Willow bark, a natural source of salicylates (aspirin-related compounds), eased pain and fever for centuries. Bayer chemist Felix Hoffmann synthesized acetylsalicylic acid in 1897; it was sold from 1899. In 1971, Vane showed that aspirin-like drugs block prostaglandin production, explaining its pain relief and antiplatelet effect (Vane, 1971).

  • Cardiovascular era: ISIS-2 found fewer vascular deaths with aspirin after suspected heart attack (ISIS-2, 1988), and the Physicians’ Health Study reported fewer first heart attacks in healthy male doctors (Physicians’ Health Study, 1989). Use after a heart attack or stroke became standard.
  • Rise and retreat in healthy people: Daily aspirin spread among healthy adults. Three 2018 trials found small or absent net benefit: ASPREE (McNeil et al., 2018), ASCEND (Bowman et al., 2018) and ARRIVE, funded by aspirin maker Bayer, which attributed its low event rate to contemporary risk management (Gaziano et al., 2018). The US Preventive Services Task Force (USPSTF, an independent federal panel whose members earn nothing from aspirin) then narrowed its guidance (USPSTF, 2022).
  • Cancer and longevity interest: Rothwell’s group reported fewer cancer deaths in long-term trial follow-up (Rothwell et al., 2011), and aspirin extended lifespan in male mice (Strong et al., 2008). ASPREE’s excess cancer deaths in people starting after 70 (McNeil et al., 2018) complicated this picture, and newer trials refocused on genetically defined groups.
  • What changed: The earlier trials were not overturned; lower baseline risk and better bleeding data shifted the balance for healthy people, while the cancer question remains open.

Expected Benefits

High 🟩 🟩 🟩

Fewer Heart Attacks and Ischemic Strokes ⚠️ Conflicted

Aspirin lowers heart attacks and ischemic (clot-related) strokes by preventing platelet clots on damaged plaque. Baigent’s 22-trial individual-data analysis found a large benefit after prior heart attack or stroke; Jones found 81 mg matched 325 mg. Without known disease, Zheng and Roddick’s and Guirguis-Blake’s meta-analyses and Bowman’s ASCEND in diabetes showed smaller reductions. In contrast, McNeil’s ASPREE in adults over 70 and Gaziano’s ARRIVE found no significant reduction. Net reading: benefit clearly exceeds bleeding with established disease but is small in healthy people and absent when started after 70.

Magnitude: After a heart attack or stroke, serious vascular events 6.7% versus 8.2% per year with control (Baigent et al., 2009); 81 mg versus 325 mg 7.28% versus 7.51%, hazard ratio (HR, the relative event rate over time; below 1 means fewer events) 1.02, 95% confidence interval (CI, the range likely to contain the true value) 0.91–1.14 (Jones et al., 2021). Without known disease, 57.1 versus 61.4 events per 10,000 participant-years (years of follow-up added up across all participants), HR 0.89 (95% credible interval, the Bayesian counterpart of a confidence interval, 0.84–0.95), number needed to treat (NNT, how many people must take it for one to avoid an event) 265 (Zheng & Roddick, 2019; figures as corrected by the 2019 erratum); odds ratio (OR, a relative measure of odds read like the HR) 0.90 (CI 0.85–0.95), absolute differences across trials −2.5% to −0.1% (range as corrected by a 2022 erratum) (Guirguis-Blake et al., 2022); diabetes 8.5% versus 9.6% with placebo, rate ratio (event rate with aspirin divided by the rate with placebo) 0.88 (CI 0.79–0.97) (Bowman et al., 2018); ARRIVE 4.29% versus 4.48%, HR 0.96 (CI 0.81–1.13) (Gaziano et al., 2018); age ≥70 10.7 versus 11.3 events per 1,000 participant-years, HR 0.95 (CI 0.83–1.08) (McNeil et al., 2018).

Fewer Vein Clots After a First Unprovoked Clot or Major Orthopedic Surgery ⚠️ Conflicted

After finishing anticoagulants (drugs that block clotting factors) for a first unexplained deep-vein or lung clot, aspirin lowers repeat clots: INSPIRE pooled Becattini’s WARFASA and Brighton’s ASPIRE placebo-controlled trials (1,224 patients) with low major bleeding, although ASPIRE alone missed significance. The PEP trial group found 160 mg after hip-fracture surgery cut clots by about a third. After joint replacement, Anderson’s EPCAT II found aspirin similar to rivaroxaban, while Sidhu’s CRISTAL found more clots than enoxaparin. Net reading: aspirin prevents vein clots, though less reliably than anticoagulants.

Magnitude: Recurrent venous thromboembolism (VTE, clots in deep veins or lungs) 5.1% per year with aspirin versus 7.5% per year with placebo, HR 0.68 (CI 0.51–0.90); major bleeding 0.5% versus 0.4% per year (Simes et al., 2014); ASPIRE alone 4.8% versus 6.5% per year, HR 0.74 (CI 0.52–1.05) (Brighton et al., 2012); after hip-fracture surgery, clots 1.6% versus 2.5% with placebo, 36% proportional reduction (CI 19–50%) (PEP Trial Collaborative Group, 2000); after joint replacement, symptomatic VTE 0.64% versus 0.70% with rivaroxaban, difference 0.06 percentage points (CI −0.55 to 0.66) (Anderson et al., 2018), and 3.45% versus 1.82% with enoxaparin, difference 1.97 percentage points (CI 0.54–3.41) (Sidhu et al., 2022).

Prevention of Pre-eclampsia in High-Risk Pregnancy ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Low-dose aspirin started in pregnancy lowers the chance of pre-eclampsia (pregnancy-related high blood pressure with organ damage), preterm birth and fetal or newborn death in women at risk. Duley and colleagues’ Cochrane review pooled 77 trials from many groups, and Rolnik’s ASPRE trial found a large reduction in preterm pre-eclampsia with 150 mg. In contrast, the CLASP trial of 60 mg in 9,364 women found no significant reduction. This bears on pregnancy outcomes, not on healthy lifespan. Net reading: benefit is likely in high-risk women, clearest for early-onset disease.

Magnitude: Pre-eclampsia relative risk (RR, risk with treatment divided by risk without) 0.82 (CI 0.77–0.88), 16 fewer cases per 1,000 women treated (Duley et al., 2019); preterm pre-eclampsia 1.6% versus 4.3% with placebo, OR 0.38 (CI 0.20–0.74) (Rolnik et al., 2017); pre-eclampsia with protein in the urine 12% lower with aspirin, not significant (CLASP Collaborative Group, 1994).

Medium 🟩 🟩

No benefit reaches Medium: the remaining positive cancer signals come from long-term observational follow-up of trials, which a Cochrane review (Cai et al., 2026) rated very low certainty, while randomized trials in older adults found no benefit.

Low 🟩

Fewer Cancers and Cancer Deaths, Mainly Bowel Cancer ⚠️ Conflicted

Rothwell’s trial follow-ups, the Women’s Health Study and Burn’s Bayer-co-funded CAPP2 (600 mg) in Lynch syndrome (inherited bowel-cancer risk) suggest fewer colorectal (bowel) cancers long-term. But ASPREE found more cancer deaths after 70, and Cai’s Cochrane review found little effect within 15 years. Net reading: benefit uncertain beyond Lynch syndrome.

Magnitude: Colon cancer incidence HR 0.76 (CI 0.60–0.96) and death HR 0.65 (CI 0.48–0.88); absolute reduction of 1.76% (CI 0.61–2.91) in 20-year risk of fatal colorectal cancer after 5 years of 75–300 mg (Rothwell et al., 2010); cancer deaths 562 versus 664, OR 0.85 (CI 0.76–0.96) across 34 trials (Rothwell et al., 2012); colorectal cancer HR 0.80 (CI 0.67–0.97) with alternate-day 100 mg (Cook et al., 2013); polyps 33% versus 37% with placebo, risk ratio 0.83 (CI 0.72–0.96) (Cole et al., 2009); Lynch syndrome colorectal cancer 9% versus 13% with placebo, HR 0.65 (CI 0.43–0.97) (Burn et al., 2020); ASPREE colorectal cancer HR 1.01 (CI 0.84–1.21) and cancer death HR 1.15 (CI 1.03–1.29) over 8.6 years (Orchard et al., 2026); general-population colorectal cancer HR 1.00 (CI 0.81–1.24) at 5–10 years and 0.95 (CI 0.77–1.17) at 10–15 years (Cai et al., 2026); in chronic hepatitis B or C, liver cancer 4.0% versus 8.3% over follow-up, difference −4.3 percentage points (CI −5.0 to −3.6), adjusted HR 0.69 (CI 0.62–0.76) (Simon et al., 2020).

Longer Healthy Lifespan ⚠️ Conflicted

Aspirin extended lifespan in male, not female, mice (Strong et al., 2008). In contrast, ASPREE found no gain in survival free of dementia and disability in adults over 70, also over about ten years of follow-up. Net reading: no human evidence of longer healthy life.

Magnitude: Death, dementia or persistent disability 21.5 versus 21.2 events per 1,000 participant-years, HR 1.01 (CI 0.92–1.11) (McNeil et al., 2018); about ten-year follow-up HR 1.01 (CI 0.95–1.08) (Shah et al., 2025).

Prevention of Dementia and Cognitive Decline ⚠️ Conflicted

Aspirin was proposed to protect the brain by preventing small clots and inflammation. In contrast, ASPREE found no effect on dementia, mild cognitive impairment or cognitive change, and a Cochrane review agreed. Net reading: no protective effect.

Magnitude: Triggers for dementia assessment HR 1.03 (CI 0.91–1.17) and probable Alzheimer’s disease HR 0.96 (CI 0.74–1.24) (Ryan et al., 2020); dementia RR 0.98 (CI 0.83–1.15) (Jordan et al., 2020).

Prevention of Depression ⚠️ Conflicted

Aspirin was proposed to lower depression risk through anti-inflammatory effects. In contrast, the ASPREE-D trial in 19,114 older adults found no difference in new depressive symptoms. Net reading: no preventive effect in healthy older adults.

Magnitude: New depressive symptoms 70.4 versus 69.1 per 1,000 person-years (years of follow-up added up across all participants), HR 1.02 (CI 0.96–1.08) (Berk et al., 2020).

Speculative 🟨

Fasting-Like Cellular Self-Cleaning

Salicylate, aspirin’s breakdown product, blocked EP300 and induced autophagy in cells and worms, mimicking calorie restriction (Pietrocola et al., 2018). The basis is mechanistic and animal-only.

Benefit-Modifying Factors

  • Genetics – lipoprotein(a): Carriers of rs3798220-C, a variant in the LPA gene (which sets lipoprotein(a), an inherited clot-promoting cholesterol particle), had fewer major cardiovascular events on aspirin without significantly more bleeding (Lacaze et al., 2022).
  • Genetics – inherited and tumor variants: Lynch syndrome carriers showed fewer bowel cancers on aspirin (Burn et al., 2020); after surgery, tumors with PI3K-pathway mutations recurred less often (Martling et al., 2025).
  • Baseline biomarkers – body weight and blood-cell mutations: 75–100 mg prevented cardiovascular events only in people under 70 kg (Rothwell et al., 2018); clonal hematopoiesis (age-related expansion of mutated blood stem cells) predicted cancer benefit in older adults (Thao et al., 2025).
  • Sex: In primary prevention, aspirin mainly reduced ischemic stroke in women and heart attack in men, with similar overall cardiovascular reduction (Berger et al., 2006).
  • Pre-existing conditions: Benefit is largest after a heart attack, stroke (Baigent et al., 2009) or unprovoked vein clot; in diabetes without heart disease, prevented events were largely offset by bleeding (Bowman et al., 2018).
  • Age: Starting at 70 or older brought no cardiovascular (McNeil et al., 2018) or healthy-lifespan benefit (McNeil et al., 2018), while cancer benefits need 5–10 years to emerge, favoring midlife starts (Rothwell et al., 2011).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Major Bleeding, Mainly from the Gut ⚠️ Conflicted

Aspirin raises serious bleeding, chiefly from the stomach and upper intestine, by blocking platelet clotting and weakening the stomach lining. The excess appears across independent trials: Zheng and Roddick’s meta-analysis, McNeil’s ASPREE (analyzed by Mahady), Bowman’s ASCEND and Gaziano’s ARRIVE (mostly mild gut bleeds). Risk rises with age, smoking, high blood pressure, kidney disease and obesity; some bleeds need transfusion. In contrast, Simes’ INSPIRE pooled trials after a vein clot found no significant excess. Net reading: a modest excess, consistent across the larger trials.

Magnitude: Major bleeding 23.1 versus 16.4 per 10,000 participant-years, HR 1.43 (credible interval 1.30–1.56), number needed to harm (NNH, how many people must take it for one to be harmed) 210 (Zheng & Roddick, 2019; figures as corrected by the 2019 erratum); diabetes major bleeding 4.1% versus 3.2%, rate ratio 1.29 (CI 1.09–1.52) (Bowman et al., 2018); gastrointestinal bleeding (mostly mild) 0.97% versus 0.46%, HR 2.11 (CI 1.36–3.28) (Gaziano et al., 2018); upper gastrointestinal bleeds 89 versus 48, HR 1.87 (CI 1.32–2.66) in adults over 70 (Mahady et al., 2021); after a first unprovoked vein clot, major bleeding 0.5% versus 0.4% per year with placebo (Simes et al., 2014).

Bleeding Inside the Skull

Aspirin increases intracranial hemorrhage (bleeding within the skull), including subdural bleeding (between brain and skull) and hemorrhagic stroke (stroke from a burst vessel), which carry high death and disability rates. Huang and colleagues’ meta-analysis of 13 primary-prevention trials and the Baigent individual-data analysis both found an excess. Relative risk of bleeding within brain tissue was higher in people of Asian ancestry and with low body mass index (BMI, weight relative to height).

Magnitude: Any intracranial bleeding RR 1.37 (CI 1.13–1.66), about 2 additional cases per 1,000 people (Huang et al., 2019); hemorrhagic stroke 0.04% versus 0.03% per year (Baigent et al., 2009).

Minor Bleeding: Nosebleeds and Bruising

Daily aspirin increases minor bleeding, mainly nosebleeds and easy bruising, because platelets plug small vessel injuries less effectively. Two independent randomized trials show the excess: Meade’s Thrombosis Prevention Trial of 75 mg in men at high heart risk, where episodes were more frequent than with placebo and more frequent still with added low-intensity warfarin, and Gaziano’s ARRIVE trial of 100 mg. Age did not change the risk in Meade’s trial. Such bleeds usually stop on their own, unlike the major bleeds above.

Magnitude: Treatment-related nosebleeds 1.85% versus 0.89% with placebo over a median of 5 years (Gaziano et al., 2018); more minor nosebleeds and bruises with 75 mg than with placebo, less often in smokers, reported as a direction only (Meade et al., 1992).

Medium 🟥 🟥

Iron-Deficiency Anemia

Daily aspirin increased new anemia (low red-blood-cell count) and lowered ferritin (the body’s iron-storage protein) in healthy older adults, likely through slow, unnoticed blood loss from the gut. The finding comes from a single trial, McQuilten’s analysis of ASPREE, and persisted when major bleeds were excluded. It is slow and reversible but can cause fatigue and reduced exercise capacity.

Magnitude: Anemia 51.2 versus 42.9 events per 1,000 person-years, HR 1.20 (CI 1.12–1.29); ferritin below 45 µg/L at 3 years in 13% versus 9.8% with placebo (McQuilten et al., 2023).

Serious Falls in Older Adults

In Barker’s ASPREE-FRACTURE substudy of 16,703 adults aged 70 and older, aspirin did not reduce fractures but was linked to more falls needing hospital care. The mechanism is unknown. This is a single trial in mostly White Australians, and the finding has not been replicated.

Magnitude: Serious falls 884 versus 804, incidence rate ratio (IRR, ratio of event rates) 1.17 (CI 1.03–1.33); fractures HR 0.97 (CI 0.87–1.06) (Barker et al., 2022).

Peptic Ulcer and Indigestion ⚠️ Conflicted

Aspirin weakens the protective stomach lining, causing dyspepsia (indigestion, upper-abdominal discomfort) and peptic ulcers (sores in the stomach or duodenum, the first part of the small intestine), the usual origin of serious gut bleeding. Cook’s Women’s Health Study follow-up found more self-reported ulcers with alternate-day 100 mg. In contrast, Meade’s smaller Thrombosis Prevention Trial found no increase in peptic ulceration or indigestion with 75 mg. Net reading: a modest ulcer excess is likely with long-term use.

Magnitude: Peptic ulcer HR 1.17 (CI 1.09–1.27) (Cook et al., 2013); no increase in peptic ulceration or indigestion reports with 75 mg versus placebo, reported without an outcome figure (Meade et al., 1992).

Gout Flares and Higher Uric Acid

Low doses of aspirin reduce kidney excretion of uric acid, raising blood levels and triggering gout attacks in people with gout. Zhang’s case-crossover study (comparing each person’s periods on and off aspirin) found more attacks after two days of use, strongest at 100 mg or less, and Caspi’s study in older inpatients showed uric-acid retention at 75 mg. Use of allopurinol (a uric-acid-lowering drug) removed the excess.

Magnitude: Gout attacks OR 1.91 (CI 1.32–2.85) with ≤100 mg on two consecutive days versus no aspirin (Zhang et al., 2014); 15% lower uric-acid excretion at 75 mg, no control group (Caspi et al., 2000).

Low 🟥

Aspirin-Exacerbated Respiratory Disease

Some adults with asthma react to aspirin with wheezing, nasal congestion and flushing (aspirin-exacerbated respiratory disease, AERD: asthma with nasal polyps flaring after COX-1 inhibitors). Rajan’s meta-analysis of 27 prevalence studies, none with a comparison group, found it commonest in severe asthma. The labeling lists it as a contraindication (labeling).

Magnitude: Prevalence 7.15% (CI 5.26–9.03%) among adults with asthma and 14.89% in severe asthma; no control group; the source has no comparison group (Rajan et al., 2015).

Higher Death Rate When Started After 70 ⚠️ Conflicted

ASPREE found more deaths, mostly from cancer, with aspirin started after 70. In contrast, extended ASPREE follow-up and pooled trials (Guirguis-Blake et al., 2022) found no significant mortality effect. Net reading: no survival gain, and a possible early excess in older starters.

Magnitude: All-cause death 12.7 versus 11.1 per 1,000 person-years, HR 1.14 (CI 1.01–1.29) (McNeil et al., 2018); about ten-year deaths HR 1.06 (CI 0.99–1.14) (Shah et al., 2025).

An Australian cohort linked regular aspirin use to wet age-related macular degeneration (AMD, central vision loss from retinal ageing). In contrast, two randomized trials found no increase in AMD overall, though neither reported wet AMD separately. Net reading: no causal risk shown.

Magnitude: Cohort 15-year wet AMD incidence 9.3% in regular users versus 3.7% in nonusers, adjusted OR 2.46 (CI 1.25–4.83) (Liew et al., 2013); trials, any AMD 19.4% versus 19.1%, RR 1.02 (CI 0.85–1.22) (Robman et al., 2024) and visually significant AMD 111 versus 134 cases, HR 0.82 (CI 0.64–1.06) (Christen et al., 2009).

Heart Failure ⚠️ Conflicted

Mujaj and colleagues’ pooled analysis of six observational cohorts linked aspirin use to more new heart failure (the heart pumping too weakly). In contrast, Zhou’s analysis of the ASPREE trial in older adults found no significant increase. Net reading: no causal risk shown in healthy older adults.

Magnitude: Cohorts HR 1.26 (CI 1.12–1.41) (Mujaj et al., 2022); trial 2.3 versus 2.0 events per 1,000 person-years with placebo, HR 1.15 (CI 0.86–1.54) (Zhou et al., 2022).

Speculative 🟨

Risk-Modifying Factors

  • Genetics and ancestry: People of Asian ancestry had a higher relative risk of intracerebral (within brain tissue) bleeding on low-dose aspirin (Huang et al., 2019); no validated gene test predicts aspirin bleeding risk.
  • Baseline biomarkers: Low hemoglobin or ferritin at the start leaves less reserve against aspirin’s added anemia risk (McQuilten et al., 2023); low baseline albumin amplified uric-acid retention at 75 mg (Caspi et al., 2000).
  • Body weight: Among people under 50 kg taking 75–100 mg, all-cause death was higher on aspirin, HR 1.52 (Rothwell et al., 2018).
  • Sex: Aspirin raised bleeding to a similar degree in women and men, OR 1.68 and 1.72 respectively (Berger et al., 2006).
  • Pre-existing conditions: Smoking, high blood pressure, chronic kidney disease and obesity raised serious gut-bleeding risk in ASPREE (Mahady et al., 2021); prior ulcers, bleeding disorders and asthma with nasal polyps raise risk further (labeling).
  • Age: Five-year serious gut-bleeding risk was 0.25% for a 70-year-old without aspirin and up to 5.03% for an 80-year-old on aspirin with risk factors (Mahady et al., 2021).

Key Interactions & Contraindications

Prescription drugs

  • Anticoagulants (warfarin, apixaban, rivaroxaban, heparin): Caution; oral anticoagulants with aspirin doubled upper-gut bleeding versus aspirin alone, RR 2.00 (García Rodríguez et al., 2011); aspirin can displace warfarin from protein binding (labeling). A proton pump inhibitor (PPI, stomach-acid reducer) is commonly added.
  • Other antiplatelet drugs (platelet-blocking drugs: clopidogrel, ticagrelor): Caution; adding one to aspirin doubled bleeding, RR 2.21, in stroke trials (Odat et al., 2025). Guidelines limit combined use to defined heart or stroke indications.
  • Selective serotonin reuptake inhibitors (SSRIs, an antidepressant class: sertraline, fluoxetine, escitalopram): Monitor; aspirin plus an SSRI raised bleeding versus aspirin alone, HR 1.42 (Labos et al., 2011); a PPI is commonly added for stomach protection.
  • Methotrexate: Caution; labeling warns salicylate reduces methotrexate kidney clearance, risking bone-marrow toxicity (labeling), though 3.4 g/day aspirin did not change overall clearance in a small rheumatoid-arthritis study (Furst et al., 1990); blood counts and kidney function are monitored.
  • Blood-pressure drugs (ACE inhibitors, blood-pressure-hormone blockers, e.g., lisinopril; beta blockers, heart-rate-slowing, e.g., metoprolol; diuretics, urine-increasing, e.g., furosemide): Monitor; labeling warns of blunted effects (labeling), but 75 mg did not alter treated blood pressure (Zanchetti et al., 2002).
  • Anticonvulsants (anti-seizure drugs: valproic acid, phenytoin): Monitor; salicylate displaces them from protein binding (labeling); fever-reducing aspirin doses raised the free valproate fraction from 12% to 43% in children (Orr et al., 1982); valproate levels are checked.
  • Uricosurics (drugs that raise uric-acid excretion: probenecid, sulfinpyrazone): Caution; labeling says salicylates antagonize their uric-acid-lowering action (labeling), but 325 mg/day aspirin did not alter probenecid’s effect in a small gout crossover study (Harris et al., 2000); serum uric acid is rechecked.
  • Corticosteroids (anti-inflammatory steroid drugs: prednisone, dexamethasone): Caution; with high-dose oral corticosteroids, upper-gut bleeding was higher than with aspirin alone, RR 4.43, but not with low doses (García Rodríguez et al., 2011); a PPI is commonly added for stomach protection.
  • Oral glucose-lowering drugs (sulfonylureas: glipizide, glimepiride): Monitor; labeling warns moderate aspirin doses may increase their effect, leading to hypoglycemia (low blood sugar) (labeling); blood glucose is checked when aspirin is started.
  • Acetazolamide: Caution; labeling warns that aspirin competes with this diuretic for kidney secretion, raising acetazolamide levels and risking toxicity (labeling); kidney function and toxicity symptoms are monitored.
  • Metamizole (dipyrone, a non-opioid pain reliever): Caution; co-medication after a cardiovascular event was linked to higher mortality than aspirin alone, HR 1.66 (Polzin et al., 2021); taking aspirin before metamizole preserved aspirin’s platelet inhibition in a small study (Polzin et al., 2015).

Over-the-counter medications

  • Ibuprofen: Avoid taking before aspirin; ibuprofen given first blocked aspirin’s lasting platelet inhibition, while aspirin taken two hours before a single ibuprofen dose kept its effect (Catella-Lawson et al., 2001).
  • Other NSAIDs (naproxen, diclofenac): Caution; concurrent use raises bleeding and kidney risk (labeling); naproxen weakened aspirin’s lasting platelet inhibition, less so when taken 2 hours after aspirin (Anzellotti et al., 2011); diclofenac did not (Catella-Lawson et al., 2001).
  • Acetaminophen (paracetamol): No interaction found; it did not interfere with aspirin’s platelet inhibition (Catella-Lawson et al., 2001).
  • Proton pump inhibitors (PPIs, stomach-acid reducers: omeprazole, pantoprazole): Beneficial; co-use was linked to 73% fewer peptic ulcers and 50% less gut bleeding, though evidence is weak (Tran-Duy et al., 2015).
  • Alcohol: Caution; three or more drinks daily increases aspirin-related bleeding (labeling); ethanol potentiated aspirin’s prolongation of bleeding time in a human study (Deykin et al., 1982).

Supplements

  • Omega-3 fatty acids (fish oil, krill oil): Monitor; they alter platelet function, but a review found no rise in clinically significant bleeding, including with antiplatelet drugs (Wachira et al., 2014).
  • Ginkgo biloba extract: Monitor; 300 mg/day with 325 mg aspirin did not change platelet tests or bleeding over 4 weeks in a small trial (Gardner et al., 2007).
  • High-dose vitamin E: Caution; 400 IU/day with 325 mg aspirin further lowered platelet adhesiveness over 2 years in a small randomized trial, and both hemorrhagic strokes, a nonsignificant difference, occurred on the combination (Steiner et al., 1995).
  • Additive antiplatelet supplements (garlic, curcumin, nattokinase, a clot-dissolving soybean enzyme): Caution (theoretical); each has platelet- or clot-inhibiting activity that may add to aspirin’s bleeding effect; no human interaction study with aspirin was identified.

Other interventions

  • Surgery, dental extraction and polypectomy (bowel-polyp removal): Caution; aspirin increased major bleeding without preventing heart attacks around noncardiac surgery, HR 1.23 (Devereaux et al., 2014). Interruption timing varies with the procedure and the person’s clot risk.

Populations who should avoid Low-Dose Aspirin:

  • People with allergy to NSAIDs or the syndrome of asthma, rhinitis (nasal inflammation) and nasal polyps (labeling)
  • Children and teenagers with viral infections, because of Reye’s syndrome (a rare, life-threatening brain and liver swelling) (labeling)
  • People with active peptic ulcer disease or inherited or acquired bleeding disorders such as hemophilia (inherited clotting-factor deficiency), liver disease or vitamin K deficiency (labeling)
  • Severe kidney failure with glomerular filtration rate (GFR, the kidneys’ filtering rate) below 10 mL/minute, and severe liver insufficiency (labeling)
  • Third trimester of pregnancy and the week before delivery (labeling)
  • Adults aged 60 and older without cardiovascular disease starting aspirin for primary prevention, per a USPSTF grade D recommendation; the panel’s members earn nothing from aspirin either way (USPSTF, 2022)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Lowest effective dose: 75–100 mg limits bleeding: 100 mg carried less bleeding risk than 600 mg in partly Bayer-funded CaPP3 (Burn et al., 2026), and 81 mg matched 325 mg for events and bleeding (Jones et al., 2021).
  • Bleeding-risk screen before starting: Age, smoking, high blood pressure, chronic kidney disease and obesity predicted serious gut bleeding in ASPREE (Mahady et al., 2021); prior ulcers and anticoagulant use add risk (labeling). Screening identifies higher-risk people.
  • Stomach protection: Adding a PPI to long-term low-dose aspirin was linked to fewer ulcers and bleeds (Tran-Duy et al., 2015); testing for and treating Helicobacter pylori (an ulcer-causing stomach bacterium) is common practice.
  • Ibuprofen timing: Taking aspirin at least two hours before an occasional ibuprofen dose preserved aspirin’s lasting platelet inhibition, which ibuprofen taken first blocked (Catella-Lawson et al., 2001).
  • Iron and anemia checks: Periodic hemoglobin checks catch aspirin-related anemia (McQuilten et al., 2023); ferritin below 45 µg/L, the iron-deficiency cutoff used in ASPREE, prompts review of iron status and bleeding sources.
  • Blood-pressure control: Keeping blood pressure below 130/80 mmHg, the American College of Cardiology/American Heart Association (ACC/AHA) target, whose members gain no direct revenue from it (Arnett et al., 2019), limits pressure-driven bleeding inside the skull.
  • Fall prevention after 70: Balance and strength training and home hazard review reduce exposure to the serious falls seen on aspirin (Barker et al., 2022).
  • Planned interruption for procedures: Pausing about 7 days before elective surgery, matching platelet lifespan, limits surgical bleeding; with stents or prior events, the bleeding benefit of a pause is weighed against clot risk.
  • Gout-prone users: Checking uric acid and using allopurinol, which nullified aspirin’s gout-flare excess, limits attacks (Zhang et al., 2014).
  • Warning signs: Black or bloody stools, vomiting blood, sudden severe headache or new wheezing are recognized signals of bleeding or respiratory reaction; prompt medical assessment limits harm from these events.

Therapeutic Protocol

Timing, cycling, titration and other parameters without a citation reflect common practice.

  • Standard dose: 75–100 mg once daily (81 mg in the US), the range used in modern prevention trials (Guirguis-Blake et al., 2022); ASPREE used 100 mg enteric-coated (coated to dissolve past the stomach) (McNeil et al., 2018).
  • Guideline approach (USPSTF): Ages 40–59 with ≥10% 10-year cardiovascular risk: individual decision (grade C, small net benefit); age ≥60: starting not recommended (grade D, no net benefit) (USPSTF, 2022); panel members earn nothing from aspirin.
  • Guideline approach (ACC/AHA): The ACC/AHA guideline allows 75–100 mg for selected higher-risk adults aged 40–70 without increased bleeding risk (Arnett et al., 2019); cardiologists earn no procedure revenue from this over-the-counter drug.
  • Longevity-practitioner approach: Life Extension promoted 81 mg daily for aging adults from 1983, mainly for cancer prevention (Korlov, Life Extension), but in 2019 said many low-risk adults may not need it (Faloon, Life Extension); the company sells supplements.
  • Weight-adjusted dosing (proposed): Rothwell’s analysis found 75–100 mg effective only under 70 kg and ≥325 mg effective only at 70 kg or more (Rothwell et al., 2018); untested prospectively.
  • Cancer-prevention dosing in Lynch syndrome: John Burn’s CAPP2 used 600 mg daily (Burn et al., 2020); the partly Bayer-funded CaPP3 found 100 mg similar to 600 mg with fewer bleeds (Burn et al., 2026).
  • Alternate-day option: 100 mg every other day was the Women’s Health Study regimen, with long-term colorectal benefit (Cook et al., 2013).
  • Time of day: Usually taken with breakfast or the main meal for stomach comfort; Ramón Hermida’s group proposes bedtime dosing, citing its blood-pressure effects, and compared it with morning dosing in diabetes (NCT00725127).
  • Half-life: Aspirin itself is cleared within 1–2 hours; salicylic acid lasts about 6 hours (labeling), but platelet inhibition persists for the platelet’s 7–10-day life.
  • Single versus split dose: One daily dose suffices because the platelet effect is irreversible; split dosing is not part of standard low-dose regimens.
  • Formulation: Enteric-coated tablets absorb erratically and caused apparent “resistance” in up to 49% after one 325 mg dose, unlike plain aspirin (Grosser et al., 2013).
  • Genetic factors: High-lipoprotein(a) genotypes favor benefit (Lacaze et al., 2022); Lynch syndrome supports cancer-preventive use.
  • Sex: Doses are the same for women and men; women gained mainly ischemic-stroke reduction and men heart-attack reduction (Berger et al., 2006).
  • Age: Starting at 70 or older for prevention showed no benefit and more bleeding (McNeil et al., 2018); midlife starts allow time for cancer effects.
  • Baseline biomarkers: Hemoglobin, ferritin, platelet count and kidney function at baseline frame bleeding reserve; lipoprotein(a) informs expected cardiovascular benefit.
  • Pre-existing conditions: Established artery disease supports lifelong use; diabetes, prior unprovoked vein clot and Lynch syndrome shift the balance toward use, while prior ulcers or bleeding disorders shift it against.

Discontinuation & Cycling

  • Lifelong versus short-term: After a heart attack or stroke, use is typically lifelong; cancer benefits require at least 5 years of continuous use (Rothwell et al., 2011).
  • Withdrawal effects: In long-term users, stopping without surgery or bleeding was linked to 37% more cardiovascular events, one extra event per 74 people yearly (Sundström et al., 2017; one author from AstraZeneca, maker of a competing antiplatelet drug).
  • Tapering: No taper is needed pharmacologically; platelet function recovers over about 7–10 days as new platelets replace inhibited ones.
  • Cycling: Cycling is not used; cancer and cardiovascular effects depend on continuous exposure, and no study has tested intermittent courses.
  • Late-life deprescribing (planned stopping): Whether stopping long-term aspirin benefits older adults is under study; RELEASE Norway randomizes 7,000 people aged 65+ after an acute coronary syndrome (heart attack or unstable chest pain) to stop or continue (NCT07854795).

Sourcing and Quality

  • Regulated over-the-counter drug: Low-dose aspirin is a regulated over-the-counter drug that must meet United States Pharmacopeia (USP, the official US drug-quality standards body) dissolution standards (labeling), so purity concerns typical of supplements do not apply.
  • Formulation choice: Plain or chewable tablets absorb predictably; enteric-coated tablets showed delayed, reduced absorption and apparent “resistance” after a single dose (Grosser et al., 2013).
  • Brands: Bayer, Ecotrin and pharmacy store brands contain the same active ingredient; generic 81 mg tablets are equivalent when they meet USP standards. Independent third-party testing is rarely needed for this regulated drug.
  • Storage and freshness: Moisture breaks aspirin into salicylic and acetic acids; a vinegar smell signals degradation (labeling).
  • Avoid combination products for daily use: Buffered products can carry high sodium (labeling), and caffeine or pain-reliever combinations add unneeded ingredients and hidden extra aspirin.

Practical Considerations

  • Time to effect: Platelet inhibition begins within hours of a plain tablet; cardiovascular effects appear within the first years, while cancer effects emerged only after 3–5 years or more (Rothwell et al., 2012).
  • Common pitfalls: Starting after 70 for primary prevention, taking ibuprofen before aspirin, doubling up through cold or headache products containing aspirin, and stopping abruptly without a plan after a heart event.
  • Regulatory status: Low-dose aspirin is sold over the counter; US professional labeling covers secondary prevention after heart attack, stroke or angina (chest pain from reduced heart blood flow), not primary prevention (labeling).
  • Guideline status: The USPSTF, whose members have no revenue stake in aspirin, supports individual decisions at 40–59 with higher cardiovascular risk and opposes starting at 60 or older (USPSTF, 2022).
  • Funding of the evidence: Aspirin is cheap and off-patent; ASPREE was funded by the US National Institute on Aging and ASCEND by the British Heart Foundation, while ARRIVE was funded by Bayer.
  • Payer incentives: Aspirin costs far less than anticoagulants for clot prevention or colonoscopy-based cancer prevention, giving insurers and national health systems a structural incentive to favor it, a potential bias in guidelines and research funding.

Interaction with Foundational Habits

  • Sleep: None known directly; low-dose aspirin has no documented effect on sleep quality. Bedtime versus morning dosing (indirect) was tested for cardiovascular prevention, citing bedtime blood-pressure effects (NCT00725127); registered completion June 2026, no results posted.
  • Nutrition: Potentiating for bleeding with heavy alcohol, three or more drinks daily (labeling); taking it with food eases stomach upset. Lowers iron stores, likely through slow blood loss (McQuilten et al., 2023), so iron-rich foods support reserves.
  • Exercise: None detected; aspirin did not change grip strength or gait speed over 4.7 years in older adults (Phyo et al., 2025). Contact sports and fall-prone activities carry higher bleeding consequences on aspirin.
  • Stress management: None known; low-dose aspirin has no documented effect on cortisol or the stress response. Depression prevention was tested and not found (Berk et al., 2020).

Monitoring Protocol & Defining Success

Baseline testing before starting covers a complete blood count, ferritin, kidney function, blood pressure and, in people with stomach symptoms or prior ulcers, a Helicobacter pylori test. People with gout add uric acid. These tests define bleeding reserve and identify people for whom the bleeding risk outweighs the expected benefit, such as those with anemia, low platelets or advanced kidney disease.

Ongoing monitoring follows a cadence of a blood count and blood pressure at 3 months, then every 6–12 months; ferritin yearly, or sooner if hemoglobin falls; kidney function yearly after 70. Success for a healthy user is defined less by any lab value than by the absence of bleeding, anemia and stomach problems over many years of use, since the hoped-for benefits (fewer clots and cancers) cannot be seen in an individual.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hemoglobin Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL (standard reference range) Safety check: aspirin raises anemia risk Part of a complete blood count; no fasting needed; any time of day; ASPREE measured it yearly (McQuilten et al., 2023)
Ferritin ≥45 µg/L (iron-deficiency cutoff used by McQuilten et al.) Marker expected to change: aspirin lowers iron stores Conventional reference range about 30–400 µg/L (men), 15–150 µg/L (women); inflammation falsely raises ferritin; pair with hemoglobin (McQuilten et al., 2023)
Platelet count 150–400 ×10⁹/L (standard reference range) Safety check: low platelets add to bleeding risk Part of complete blood count; low counts change the risk balance
eGFR ≥60 mL/min/1.73 m² (standard reference range) Safety check: kidney disease raises bleeding risk Estimated glomerular filtration rate (eGFR, kidney filtering capacity from a creatinine blood test); labeling advises avoiding aspirin below 10 mL/min (labeling); chronic kidney disease raised gut bleeding (Mahady et al., 2021)
Blood pressure Below 130/80 mmHg (ACC/AHA target) Safety check: high pressure raises bleeding inside the skull Target from Arnett et al., 2019, whose ACC/AHA members gain no direct revenue from it; conventional reference range below 120/80 mmHg; seated, rested, average of readings
Serum uric acid (gout-prone people) 3.5–7.2 mg/dL (standard reference range) Marker expected to change: low-dose aspirin raises uric acid Relevant only with gout or high baseline levels (Caspi et al., 2000)
Helicobacter pylori test Negative (standard reference range) Safety check: infection raises ulcer and bleeding risk Breath or stool antigen test; acid reducers can mask infection and are usually paused 2 weeks before testing

Qualitative markers:

  • Stool color (black, tarry stools signal gut bleeding)
  • Easy bruising, nosebleeds or gum bleeding
  • Indigestion, heartburn or upper-abdominal pain
  • Energy and exercise tolerance (falling levels may reflect anemia)
  • New wheezing, nasal congestion or flushing after doses
  • Balance and falls in older users

Emerging Research

  • Add-Aspirin trial: Phase III trial in about 11,000 people after treatment for breast, colorectal, stomach-esophageal or prostate cancer, testing aspirin on recurrence and survival (NCT02804815); active, registered completion October 2026, no results posted. Positive results would strengthen cancer-protective use; null results would weaken it.
  • COLCOT-T2D: Phase III trial of non-enteric-coated aspirin and colchicine (an anti-inflammatory gout drug) in 10,000 people with type 2 diabetes, primary endpoint major cardiovascular events (NCT05633810). A positive aspirin result would favor plain-tablet use in diabetes; a null result would reinforce the small net benefit seen in ASCEND (Bowman et al., 2018).
  • EASTERN trial: Phase III Korean trial of low-dose aspirin versus placebo in 1,700 patients after removal of early stomach cancer, measuring new stomach cancers (NCT04214990). A positive result would extend cancer prevention beyond the bowel; a null result would confine it there.
  • RELEASE Norway: Phase IV registry-based trial randomizing 7,000 older adults 2–8 years after a stent-treated acute coronary syndrome to stop or continue aspirin (NCT07854795). Benefit from stopping would support late-life deprescribing; harm would confirm lifelong secondary-prevention use; a null result would leave continuation to individual bleeding and clot risk.
  • CARING chronotherapy (timing-based dosing) trial: Phase IV trial in 3,200 adults with impaired glucose or diabetes comparing morning versus bedtime 100 mg (NCT00725127); registered completion June 2026, no results posted. Bedtime superiority would change timing advice; a null result would leave timing open.
  • Genetically guided cancer benefit: ALASCCA roughly halved recurrence in PI3K-altered colorectal cancer (Martling et al., 2025), and clonal hematopoiesis predicted benefit in older adults (Thao et al., 2025), pointing toward biomarker-selected use.
  • Dose in hereditary cancer: First CaPP3 results suggest 100 mg performs like 600 mg in Lynch syndrome with fewer bleeds (Burn et al., 2026); its Israeli arm (NCT02497820) registers a 5-year cancer endpoint. Confirmed equal protection would support 100 mg for Lynch carriers; a null result would keep 600 mg as the proven dose.
  • Evidence weakening the case: ASPREE’s decade-long follow-up showed no lasting healthy-lifespan benefit and a bleeding excess across the trial and follow-up periods combined (Shah et al., 2025), and no legacy cancer effect after stopping (Orchard et al., 2026).

Conclusion

Low-dose aspirin is a cheap, familiar drug that makes the blood’s clotting cells less sticky for days at a time. For health-focused adults, the evidence splits by situation. In people who already have artery disease or who have had an unexplained vein clot, the benefit is strong and well replicated. For healthy people, the picture is narrower than the once-popular “aspirin a day” habit suggested: the drop in first heart attacks and strokes is small and comes with a matching rise in serious bleeding, mostly from the gut and occasionally inside the skull.

The longer-range hopes are less settled. Bowel cancer protection is possible after many years of use begun in midlife and is clearest in people with an inherited bowel-cancer condition, but it did not appear in people who started after seventy. Large trials in older adults found no gain in healthy lifespan, dementia or mood, along with more anemia and falls, and a possible early excess of cancer deaths.

The evidence base is large and mostly publicly funded, though one key heart trial and the hereditary-cancer trials received money from the main aspirin maker, and a prominent advocate of daily aspirin sells supplements. The national task force that narrowed its use has no financial stake in aspirin either way, and heart-specialist societies earn nothing from this over-the-counter drug. For this audience, the balance depends on age at starting, bleeding risk, body size and specific genetic or medical features.

Top - Benefits - Risks - Protocol